OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer
Title: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast CancerBackground: The advent of subtype-specific treatments, particularly hormone therapies and HER2-targeted therapies, has significantly improved survival rates and quality of life for breast cancer (BC) patients. Over the last decade genomic signatures have enabled improved classification Read More
Incorporating Immunotherapy in the Management of Early-Stage Estrogen Receptor-Positive Breast Cancer
Title: Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer Publication: ESMO Open - Volume 9 - Issue 11 - 2024 1 Authors: G. Nader-Marta, A. G. Waks, S. M. Tolaney, E. L. Mayer Abstract Immune checkpoint inhibitors (ICI) have been incorporated into standard treatment regimens for Read More
Identification of Racial Disparities (ESMO 2024)
Title: Identification of racial disparities across MammaPrint® and BluePrint® subtypes in HR+HER2- breast cancer Publication: ASCO 2024, Abstract #534 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Background: Black women in Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreCost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreCost consequence model of MammaPrint in Germany
: Cost consequence model of the MammaPrint® (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany
Read MoreNeoadjuvant CT Recommendations in Black women – SSO 2024
SSO 2024 Author: Solis-Pomales et al.
Read More
